API

Mechanism of Action

Fruquintinib is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of specific enzymes, known as tyrosine kinases, which are involved in the growth and spread of cancer cells.

In particular, fruquintinib targets vascular endothelial growth factor receptors (VEGFRs), which play a crucial role in the development of blood vessels that support the growth of tumors. By inhibiting the activity of VEGFRs, fruquintinib slows down the growth of new blood vessels and restricts the blood supply to the tumor, ultimately reducing its size and slowing its progression.

Fruquintinib has been approved in China for the treatment of certain types of advanced or metastatic colorectal cancer, and it is being studied in clinical trials for its efficacy and safety in treating other types of cancer, such as non-small cell lung cancer, gastric cancer, and breast cancer.

Indication

Fruquintinib is indicated for the treatment of advanced or metastatic colorectal cancer in China. The drug is intended for patients who have received previous treatment with other chemotherapy drugs and have not responded or have stopped responding to those treatments.

It is important to note that fruquintinib is still being studied in clinical trials for its efficacy and safety in treating other types of cancer, such as non-small cell lung cancer, gastric cancer, and breast cancer. The approval status and indications for fruquintinib may vary depending on the country and the regulatory agencies involved.